DOI: https://doi.org/10.22263/2312-4156.2022.3.27
H.I. Yupatau1, V.A. Pryshchepenka1, Z.G. Yupatava2, O.A. Pryshchepenka1
Genetic peculiarities associated with interleukins exchange in patients with hepatocellular carcinoma resulting from viral hepatitis C
1Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
2The 6th City Clinical Hospital, Minsk, Republic of Belarus
Vestnik VGMU. 2022;21(3):27-34.
Abstract.
The mechanisms of hepatocellular carcinoma (HCC) formation still remain poorly understood. There are certain genetic features associated with the development of HCC.
Objectives. To establish genetic peculiarities connected with interleukin stimulation and associated with the development of hepatocellular carcinoma in patients with viral hepatitis C (HCV).
Material and methods. Genetic features of patients with liver diseases were determined by comparative analysis of gene expression in liver tissues based on the sequencing results available in open databases in 72 patients with hepatocellular carcinoma due to hepatitis C and 24 patients without any liver damage.
Results. In patients with HCC-HCV, there is an increased expression of 4330 (7.93%) genes and a reduced expression of 693 (1.27%) genes compared with healthy individuals. Among the signaling pathways associated with the activity of interleukins (IL), as well as in patients with HCC-HCV, the largest number of genes is involved in the signaling pathway of interleukin-11, IL-1, IL-4 and IL-13, IL-10.
Conclusions. An increased production of pro-inflammatory cytokines IL-1, 4, 6, 8, 13, that predominantly provide for overexpression of genes associated with the JAK/STAT signaling pathway has been established. At the same time, the production of anti-inflammatory cytokines, such as IL-10, 11, ensuring cell growth and proliferation, angiogenesis, and regulation of apoptosis processes is observed.
Keywords: hepatocellular carcinoma, viral hepatitis C, liver cancer, interleukin, signaling pathway, sequencing.
References
1. Guo P, Sun X, Feng X, Zhang C. Transforming growth factor-β1 gene polymorphisms with liver cirrhosis risk: A meta-analysis. Infect Genet Evol. 2018 Mar;58:164-70. doi: http://doi.org/10.1016/j.meegid.2017.12.019
2. Guo P-F, Jin J, Sun X. Influence of IL10 gene polymorphisms on the severity of liver fibrosis and susceptibility to liver cirrhosis in HBV/HCV-infected patients. Infect Genet Evol. 2015 Mar;30:89-95. doi: http://doi.org/10.1016/j.meegid.2014.12.011
3. Juzėnas S, Kupčinskas J, Valantienė I, Šumskienė J, Petrenkienė V, Kondrackienė J, et al. Association of HFE gene C282Y and H63D mutations with liver cirrhosis in the Lithuanian population. Medicina (Kaunas). 2016;52(5):269-275. doi: http://doi.org/10.1016/j.medici.2016.09.004
4. Wang Z, Teng D, Li Y, Hu Z, Liu L, Zheng H. A six-gene-based prognostic signature for hepatocellular carcinoma overall survival prediction. Life Sci. 2018 Jun;203:83-91. doi: http://doi.org/10.1016/j.lfs.2018.04.025
5. Andrisani OM, Studach L, Merle P. Gene signatures in hepatocellular carcinoma. Semin Cancer Biol. 2011 Feb;21(1):4-9. doi: http://doi.org/10.1016/j.semcancer.2010.09.002
6. Weitz E, Hanspers K, Digles D, Dupuis LJ. NetPath, Interleukin-11 signaling pathway (Homo sapiens). WikiPathways. Avaiable from: https://www.wikipathways.org/index.php/Pathway:WP2332. [Accessed 06th June 2022].
7. Wake MS, Watson CJ. STAT3 the oncogene – still eluding therapy? FEBS J. 2015 Jul;282(14):2600-11. doi: http://doi.org/10.1111/febs.13285
8. Pivovarova DD, Mashkina EV. Genetic risk factors for hepatitis B. Med Genetika. 2020;19(8):85-6. (In Russ.)
9. Shi H, He H, Ojha SC, Sun C, Fu J, Yan M, et al. Association of STAT3 and STAT4 polymorphisms with susceptibility to chronic hepatitis B virus infection and risk of hepatocellular carcinoma: a meta-analysis. Biosci Rep. 2019 Jun;39(6):BSR20190783. doi: http://doi.org/10.1042/BSR20190783
10. YES1 Gene – YES Proto-Oncogene 1, Src Family Tyrosine Kinase. GeneCards®: The Human Gene Database. Avaiable from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=YES1. [Accessed 06th June 2022].
11. Acuner Ozbabacan SE, Gursoy A, Nussinov R, Keskin O. The Structural Pathway of Interleukin 1 (IL-1) Initiated Signaling Reveals Mechanisms of Oncogenic Mutations and SNPs in Inflammation and Cancer. PLoS Comput Biol. 2014 Feb;10(2):e1003470. doi: http://doi.org/10.1371/journal.pcbi.1003470
12. Kandasamy K, Mohan SS, Raju R, Shivakumar K, Sameer GSK, Venugopal AK, et al. NetPath: a public resource of curated signal transduction pathways. Genome Biol. 2010 Jan;11(1):R3. doi: http://doi.org/10.1186/gb-2010-11-1-r3
13. Hutchins AP, Diez D, Miranda-Saavedra D. The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genomics. 2013 Nov;12(6):489-98. doi: http://doi.org/10.1093/bfgp/elt028
14. Verma R, Balakrishnan L, Sharma K, Ahmad Khan A, Advani J, Gowda H, et al. A network map of Interleukin-10 signaling pathway. J Cell Commun Signal. 2016 Mar;10(1):61-7. doi: http://doi.org/10.1007/s12079-015-0302-x
Information about authors:
H.I. Yupatau – Doctor of Medical Sciences, professor, head of the Chair of Internal Diseases Propedeutics, Vitebsk State Order of Peoples’ Friendship Medical University;
V.A. Pryshchepenka – Candidate of Medical Sciences, associate professor of the Chair of Internal Diseases Propedeutics, Vitebsk State Order of Peoples’ Friendship Medical University, https://orcid.org/0000-0003-1097-918X
E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Viachaslau A. Pryshchepenka;
Z.G. Yupatava – intern doctor, the 6th City Clinical Hospital of Minsk;
O.A. Pryshchepenka – postgraduate of the Pediatrics Chair No. 2, Vitebsk State Order of Peoples’ Friendship Medical University.
